S&P Futures
2,427.25
-2.25 (-0.09%)Dow Futures
21,712.00
-21.00 (-0.10%)
| Previous Close | 57.34 |
| Open | 57.30 |
| Bid | 52.00 x 100 |
| Ask | 59.00 x 100 |
| Day's Range | 56.54 - 57.91 |
| 52 Week Range | 54.50 - 70.16 |
| Volume | 1,021,763 |
| Avg. Volume | 1,530,084 |
| Market Cap | 10.81B |
| Beta | 1.06 |
| PE Ratio (TTM) | 9.29 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Motley Fool•2 days ago
3 Warren Buffett Stocks to Buy Right Now
Warren Buffett likes Apple, DaVita, and MasterCard. So should you.
- Thomson Reuters StreetEvents•5 days ago
Edited Transcript of DVA earnings conference call or presentation 1-Aug-17 9:00pm GMT
Q2 2017 DaVita Inc Earnings Call
- Reuters•11 days ago
Fresenius Medical banks on home dialysis with $2 bln NxStage acquisition
Germany's Fresenius Medical Care (FMC) has struck a $2 billion deal to acquire U.S. home dialysis equipment maker NxStage Medical Inc, looking to capitalise on a trend for more patients to opt for domestic treatment. FMC, the world leader in dialysis services and also a maker of medical gear, said on Monday its cash offer was worth $30 per Nxstage share, a 22 percent premium to the target's average price over the past 90 days. One motive for FMC's move into cheaper home dialysis is that the U.S. healthcare system is shifting to lump-sum reimbursements for the treatment of chronically ill patients rather than paying for all the services provided.
